Application Nr Approved Date Route Status External Links
ANDA074260 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Carbidopa And Levodopa Tablets, Usp Are Indicated In The Treatment Of Parkinson's Disease, Post-Encephalitic Parkinsonism, And Symptomatic Parkinsonism That May Follow Carbon Monoxide Intoxication Or Manganese Intoxication. Carbidopa Allows Patients Treated For Parkinson's Disease To Use Much Lower Doses Of Levodopa. Some Patients Who Responded Poorly To Levodopa Have Improved On Carbidopa And Levodopa. This Is Most Likely Due To Decreased Peripheral Decarboxylation Of Levodopa Caused By Administration Of Carbidopa Rather Than By A Primary Effect Of Carbidopa On The Nervous System. Carbidopa Has Not Been Shown To Enhance The Intrinsic Efficacy Of Levodopa. Carbidopa May Also Reduce Nausea And Vomiting And Permit More Rapid Titration Of Levodopa.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Name Structure ZINC ID(s)
1. Carbidopa CARBIDOPA ZINC19168887
2. Levodopa LEVODOPA ZINC895199

Comments